Biosimilar Rituximab Approved in Europe for Non-Hodgkin Lymphoma

June 19, 2017 – The European Commission (EC) has approved the rituximab biosimilar (GP2013) to treat patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. Rituximab biosimilar (GP2013) is approved for use in all indications of the reference medicine, subcutaneous rituximab. Subcutaneous rituximab has been available in the European Union since 2014, and is approved in nearly 50 other countries … (leggi tutto)